⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

August 1, 2025

Supplemental Figure 5 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer

Rosa A. van Amerongen Sander Tuit Dennis F.G. Remst Anne K. Wouters Sterre L. Siekman Renate S. Hagedoorn Dirk M. van der Steen Michel G.D. Kester Arnoud H. de Ru Geertje van der Horst Masashi Matsuda Fumihiko Ishikawa Peter A. van Veelen J.H. Frederik Falkenburg Mirjam H.M. Heemskerk

View at Publisher

Ask AI

Bookmark

Share

Key Points

TCR-based therapy directed against KLK4 demonstrates significant efficacy for prostate cancer treatment.
IFN-γ production measured in T cell clones shows positive outcomes post coculture with various EBV-LCLs.
The study utilized a range of HLA alleles, representative of the Caucasian population, to assess therapy effectiveness.
Results suggest that targeting kallikrein-related peptidase 4 is a promising approach for safe prostate cancer therapies.

Implication

TCR-based therapy improves IFN-γ production in EBV-LCLs from patients with prostate cancer, indicating safety and efficacy.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Amerongen et al. (2025) studied this question.

synapsesocial.com/papers/689a0c72e6551bb0af8d02c7 https://doi.org/10.1158/2326-6066.29759678

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplemental Figure 7 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
2Supplemental Figure 6 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
3Supplemental Figure 4 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
4Data from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
5Supplemental Figure 3 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025

Supplemental Figure 2 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
Supplemental Figure 1 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025
Supplemental Figure 8 from TCR-Based Therapy Directed against Kallikrein-Related Peptidase 4 Is Safe and Effective against Prostate Cancer2025